Sorroche Bruna Pereira, Talukdar Fazlur Rahman, Lima Sheila Coelho Soares, Melendez Matias Eliseo, de Carvalho Ana Carolina, de Almeida Gisele Caravina, De Marchi Pedro, Lopes Monique, Ribeiro Pinto Luis Felipe, Carvalho André Lopes, Herceg Zdenko, Arantes Lidia Maria Rebolho Batista
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, SP, Brazil.
Epigenetics Group, International Agency for Research on Cancer, 69008 Lyon, France.
Cancers (Basel). 2021 Jun 11;13(12):2915. doi: 10.3390/cancers13122915.
The identification of molecular markers in negative surgical margins of oral squamous cell carcinoma (OSCC) might help in identifying residual molecular aberrations, and potentially improve the prediction of prognosis. We performed an Infinium MethylationEPIC BeadChip array on 32 negative surgical margins stratified based on the status of tumor recurrence in order to identify recurrence-specific aberrant DNA methylation (DNAme) markers. We identified 2512 recurrence-associated Differentially Methylated Positions (DMPs) and 392 Differentially Methylated Regions (DMRs) which were enriched in cell signaling and cancer-related pathways. A set of 14-CpG markers was able to discriminate recurrent and non-recurrent cases with high specificity and sensitivity rates (AUC 0.98, = 3 × 10; CI: 0.95-1). A risk score based on the 14-CpG marker panel was applied, with cases classified within higher risk scores exhibiting poorer survival. The results were replicated using tumor-adjacent normal HNSCC samples from The Cancer Genome Atlas (TCGA). We identified residual DNAme aberrations in the negative surgical margins of OSCC patients, which could be informative for patient management by improving therapeutic intervention. This study proposes a novel DNAme-based 14-CpG marker panel as a promising predictor for tumor recurrence, which might contribute to improved decision-making for the personalized treatment of OSCC cases.
在口腔鳞状细胞癌(OSCC)阴性手术切缘中鉴定分子标志物可能有助于识别残留的分子异常,并有可能改善预后预测。我们对32个根据肿瘤复发状态分层的阴性手术切缘进行了Infinium MethylationEPIC BeadChip阵列分析,以识别复发特异性异常DNA甲基化(DNAme)标志物。我们鉴定出2512个与复发相关的差异甲基化位点(DMP)和392个差异甲基化区域(DMR),它们在细胞信号传导和癌症相关通路中富集。一组14个CpG标志物能够以高特异性和敏感性率区分复发和非复发病例(AUC 0.98,= 3×10;CI:0.95 - 1)。应用基于14个CpG标志物组合的风险评分,风险评分较高的病例生存率较差。使用来自癌症基因组图谱(TCGA)的肿瘤邻近正常头颈部鳞状细胞癌(HNSCC)样本对结果进行了验证。我们在OSCC患者的阴性手术切缘中鉴定出残留的DNAme异常,这可能通过改善治疗干预为患者管理提供信息。本研究提出了一种基于DNAme的新型14个CpG标志物组合,作为肿瘤复发的有前景的预测指标,这可能有助于改善OSCC病例个性化治疗的决策。